Halucenex to get recently harvested 1st batch of psilocybe cubensis
Optimi Head of Cultivation, Todd Henderson
VANCOUVER, British Columbia, May possibly 27, 2022 (Globe NEWSWIRE) — Optimi Overall health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN) (“Optimi” or the “Company”), a homegrown, Canadian corporation producing pure, scalable, and available mushroom formulations for transformational human activities, is pleased to announce that it has entered into a supply agreement with Halucenex Daily life Sciences Inc. (“Halucenex”), a wholly owned subsidiary of Creso Pharma of Australia (ASX: CPH). Halucenex is centered in Windsor, Nova Scotia and is a life sciences enterprise concentrated on looking into novel psychedelic compounds, producing and licensing psychedelic compounds for the pharmaceutical and nutraceutical markets, and conducting clinical trials on the clinical benefits of psychedelic medication.
Also, Optimi needs to verify that the supply agreement pertains to the entirety of the Company’s not long ago harvested 1st batch of psilocybe cubensis mushrooms at its Princeton, British Columbia facility. The mushrooms will be equipped to Halucenex in the form of complete, dried mushroom fruiting bodies.
“This very first offer agreement, coming so soon immediately after our to start with finish cultivation cycle, is a effective affirmation of our determination to go after the progress of normal, GMP psilocybin,” claimed Monthly bill Ciprick, CEO of Optimi. “From this preliminary evidence-of-strategy batch, our cultivation team will go on to scale our operations to meet up with the requires of the sector, domestically and internationally with accredited entities and for specific clients in Canada in accordance to the conditions of the Unique Access Method.”
Halucenex CEO, Invoice Fleming, suggests the arrangement with Optimi is a single both firms will profit from.
“We’re quite thrilled to be relocating ahead on this offer settlement with the group at Optimi Health,” said Fleming. “Among our prime priorities in the growth of a psychedelic-assisted psychotherapeutic design for situations this sort of as panic and publish-traumatic pressure problem has been to protected a safe and sound, constant offer of GMP psilocybin.”
Licensed functions fascinated in paying for Optimi psilocybin and functional mushroom solutions ought to send out an e-mail to [email protected] exactly where a member of the revenue group will answer inside of 24 several hours.
ABOUT OPTIMI (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN)
Optimi Health Inc. is a homegrown, Canadian success tale developing and supplying organic, EU-GMP grade psilocybin and purposeful mushrooms that focus on the health and wellness markets. Built with the goal to produce scalable, all-natural mushroom formulations for transformational human ordeals, the Company’s purpose is to be the selection just one dependable, compassionate provider of protected, purely natural GMP quality psilocybin across the environment. With a vertically built-in tactic, Optimi intends to cultivate, extract, procedure and distribute substantial high-quality purposeful and psychedelic mushroom products and solutions at its two services comprising a complete of 20,000 square toes in Princeton, British Columbia.
To thoroughly look into the science of mushrooms, the Corporation has gained a investigate exemption underneath Health Canada Food and Drug Polices (FDR) for the use of psilocybin and psilocin for scientific reasons via its wholly owned subsidiary Optimi Labs Inc. Optimi has also been granted a dealer’s license beneath Canada’s Narcotic Command Laws governing possession, distribution, sale, laboratory investigation of and study and advancement of psilocybin and psilocin formulations. Optimi is fully commited to pro cultivation and quality generation topic to and in accordance with the conditions of all relevant laws and governing laws to ensure risk-free, outstanding Canadian fungi production.
Optimi was recently granted an modification to its Dealer’s Licence by Well being Canada, permitting the Enterprise to possess a quota of up to 5000kg of dried psilocybin mushrooms – the equivalent of 10kg of psilocybin – and 100g of psilocin.
Halucenex operates a 6000 sq ft health care facility in Windsor, Nova Scotia with 6 treatment method rooms and a safe laboratory committed to carrying out psychedelic-assisted psychotherapy and clinical study. Halucenex intends to sustain command about all factors of the products progress process – mycological research, extraction engineering, and synthetic formulation as perfectly as drug shipping and delivery systems, psychedelic-assisted psychotherapy and regulatory affairs.
Clinically, Halucenex is targeted on looking into psilocybin, psilocybin-derivatives, and other psychedelic drugs for the needs of managing clients suffering from PTSD and stress applying its complete psilocybin-assisted psychotherapy treatment method product. Halucenex is committed to advancing the science all-around the use of psilocybin in psychedelic-assisted psychotherapy by:
For a lot more details or to ask for an job interview, make sure you get hold of:
Media & Stakeholder Relations Advisor
Electronic mail: [email protected]
Cellular phone: +1 (902) 880 6121
This information launch includes forward‐looking statements and forward‐looking facts in the meaning of Canadian securities legislation (collectively, “forward‐looking statements”) that relate to Optimi’s present expectations and sights of foreseeable future functions. Any statements that categorical, or include discussions as to, expectations, beliefs, strategies, objectives, assumptions or potential functions or general performance (typically, but not normally, via the use of phrases or phrases these as “will very likely final result,” “are anticipated to,” “expects,” “will keep on,” “is anticipated,” “anticipates,” “believes,” “estimated,” “intends,” “plans,” “forecast,” “projection,” “strategy,” “objective,” and “outlook”) are not historical specifics and may well be forward‐looking statements and might contain estimates, assumptions and uncertainties which could cause actual final results or results to vary materially from these expressed in these kinds of forward‐looking statements. No assurance can be provided that these expectations will verify to be accurate and such forward‐looking statements bundled in this information launch must not be unduly relied upon. These statements speak only as of the day of this information release. In particular and devoid of limitation, this information launch is made up of forward‐ seeking statements pertaining to activities proposed to be done underneath the Company’s dealer’s license and associated organization associated to psilocybin and psilocin and Optimi’s strategies, aim and targets.
Forward‐looking statements are primarily based on a quantity of assumptions and are subject matter to a amount of risks and uncertainties, quite a few of which are further than Optimi’s management, which could induce precise effects and functions to differ materially from those that are disclosed in or implied by this kind of forward‐looking statements. This kind of challenges and uncertainties involve, but are not confined to, the effect and development of the COVID‐19 pandemic and other factors established forth below “Forward‐Looking Statements” and “Risk Factors” in the Company’s Annual facts Sort dated January 12, 2022, and other constant disclosure filings offered below Optimi’s profile at www.sedar.com. Optimi undertakes no obligation to update or revise any forward‐looking statements, whether as a consequence of new information, foreseeable future events or if not, apart from as may perhaps be needed by legislation. New components arise from time to time, and it is not probable for Optimi to predict all of them or evaluate the impact of each these kinds of issue or the extent to which any element, or blend of factors, may possibly result in benefits to differ materially from all those contained in any forward‐looking assertion.
Any forward‐looking statements contained in this news release are expressly experienced in their entirety by this cautionary statement.
Photos accompanying this announcement are available at